1. Home
  2. MHF vs ENTX Comparison

MHF vs ENTX Comparison

Compare MHF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

N/A

Current Price

$6.79

Market Cap

152.3M

Sector

Finance

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$2.98

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MHF
ENTX
Founded
1988
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.3M
147.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MHF
ENTX
Price
$6.79
$2.98
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
61.8K
421.3K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
4.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.77
Revenue Growth
N/A
N/A
52 Week Low
$6.63
$0.91
52 Week High
$7.64
$4.20

Technical Indicators

Market Signals
Indicator
MHF
ENTX
Relative Strength Index (RSI) 39.79 53.32
Support Level $6.65 $2.66
Resistance Level $7.04 $3.10
Average True Range (ATR) 0.09 0.23
MACD -0.00 -0.05
Stochastic Oscillator 5.56 28.41

Price Performance

Historical Comparison
MHF
ENTX

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: